Pulse Biosciences enrolls first patient in NANOCLAMP AF study for AF treatment using nPulse system

PULSE BIOSCIENCES, INC.

First procedure completed at St. Helena Hospital in St. Helena, CA with nPulse Cardiac Surgical System using nanosecond PFA.
NANOCLAMP AF is a single-arm, prospective multicenter study for safety/effectiveness of nPulse in concomitant AF procedures.
nPulse system granted FDA Breakthrough Device Designation in July 2024 and enrolled in FDA's TAP program.
Multiple U.S. and two international sites planned; study follows recent FDA IDE approval.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.